Ardelyx announced on April 10, 2025, the presentation of a post-hoc analysis from the OPTIMIZE Study at the National Kidney Foundation (NKF) Spring Clinical Meetings. The analysis focused on managing diarrhea, a common side effect of XPHOZAH (tenapanor).
The poster, titled 'Tenapanor-Treated Patients Using Over-the-Counter Antidiarrheal Agents Saw Decreased Stool Frequency and Improved Stool Consistency,' evaluated the use of loperamide. Among patients experiencing diarrhea, 9.7% using loperamide discontinued tenapanor due to diarrhea, compared to 24.6% of patients not using loperamide.
The findings suggest that loperamide can be an effective treatment option to improve diarrhea emergent with tenapanor, potentially leading to better patient adherence and sustained phosphate control. This data provides practical guidance for healthcare providers optimizing XPHOZAH treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.